DelveInsight’s “ESR1-mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the ESR1 Mutated Metastatic Breast Cancer Market with DelveInsight’s In-Depth Report @ ESR1 Mutated Metastatic Breast Cancer Market Size
Key Takeaways from the ESR1 Mutated Metastatic Breast Cancer Market Report
Stay ahead in the ESR1 Mutated Metastatic Breast Cancer Therapeutics Market with DelveInsight’s Strategic Report @ ESR1 Mutated Metastatic Breast Cancer Market Outlook
Esr1-mutated Metastatic Breast Cancer Epidemiology Segmentation
Download the report to understand which factors are driving ESR1 Mutated Metastatic Breast Cancer epidemiology trends @ ESR1 Mutated Metastatic Breast Cancer Prevalence
ESR1 Mutated Metastatic Breast Cancer Marketed Drugs
ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group. In January 2023, the US FDA approved ORSERDU for treating postmenopausal women or adult men with ER+, HER2−, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Later in September 2023, the drug also got approved in Europe.
ESR1 Mutated Metastatic Breast Cancer Emerging Drugs
Camizestrant (AZD9833) is an oral SERD that has shown antitumor efficacy in a range of preclinical models of breast cancer. In June 2020, AstraZeneca initiated a Phase III clinical trial, SERENA-6, to evaluate the Safety and Efficacy of AZD9833 in combination with a CDK4/6 inhibitor (palbociclib or abemaciclib) for the treatment of patients with HR+ HER2− metastatic breast cancer with a detectable ESR1 mutation. As per Astrazeneca’s pipeline, Camizestrant’s + CDK4/6 inhibitor’s estimated filing acceptance in 1st line HR+ HER2- ESR1m breast cancer is 2025. Apart from that, the indication for SERENA-6 has been granted Fast Track Designation (FTD) by the US FDA.
Lasofoxifene is being investigated as a potent, bioavailable selective estrogen receptor modulator (SERM) with a differentiated safety profile that could prove useful in treating postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+ breast cancer. Lasofoxifene’s bioavailability and activity in estrogen receptor mutations could hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical needs need.
Get In-Depth Knowledge on ESR1 Mutated Metastatic Breast Cancer Market Trends and Forecasts with DelveInsight @ ESR1 Mutated Metastatic Breast Cancer Treatment Market
ESR1 Mutated Metastatic Breast Cancer Drugs Market Insights
The existing ESR1 treatment is mainly dominated by classes such as aromatase inhibitors, aromatase inhibitors + CDK4/6 inhibitors, and CDK4/6 + SERDs. For postmenopausal women with HR-positive, HER2-positive recurrent/Stage IV breast cancer, the preferred options available include fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, and abemaciclib; category 1) or for those with tumor PIK3CA mutations, fulvestrant with alpelisib; everolimus with either an AI, tamoxifen or fulvestrant; monotherapy with fulvestrant, nonsteroidal or steroidal AI, or SERM.
ESR1-mutated Metastatic Breast Cancer Market Outlook
ESR1 mutations have increased, even with aromatase inhibitor (AI) therapy, indicating their adaptability to AI therapeutic conditions. In addition, the presence of ESR1 mutations has been correlated with a shorter time to treatment failure, as metastatic breast cancer (MBC) patients with ESR1 mutations exhibit an inadequate response to and shorter duration of effective endocrine control. Suppose AI treatment provides selection pressure for mutant-bearing clonal outgrowth in patients.
Esr1-mutated Metastatic Breast Cancer Therapies and Key Companies
Scope of the ESR1 Mutated Metastatic Breast Cancer Market Report
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance in the 7MM
7 Disease Background and Overview
8 Epidemiology and patient Population of the 7MM
9 Patient Journey
10 Key Endpoints in ESR1-mutated Metastatic Breast Cancer
11 Key Cross Competition of Drugs
12 Marketed Drug
13 Emerging Drugs
14 ESR1-mutated Metastatic Breast Cancer: The 7MM Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
17.1 KOL Interviews
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/wolman-disease-market
